Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Methylprednisolone Tablets (for dogs), officially classified as a Category 5 new veterinary drug [1] Group 1 - The new veterinary drug, Methylprednisolone Tablets (for dogs), is developed in collaboration with six other companies and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug can be used as part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation in the eyes/ears, as well as other inflammatory/allergic diseases effectively treated with glucocorticoids, including immune-mediated diseases [1]

Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Zhejiang Haizheng Animal Health Products Co., has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), marking a significant step in the company's strategic expansion in the veterinary medicine sector [1] Group 1 - The new veterinary drug product has been granted a Class V New Veterinary Drug Registration Certificate by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The approval indicates that the product complies with the relevant regulations of the Veterinary Drug Administration and the Veterinary Drug Registration Measures [1] - This development is expected to enhance the company's market competitiveness in the veterinary medicine segment [1]

Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Haizheng Animal Health, has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), marking a significant step in the company's strategic positioning in the veterinary medicine sector [2]. Group 1 - The product, Methylprednisolone Tablets (for dogs), is intended for the treatment of canine inflammatory and allergic diseases [2]. - The approval was granted by the Ministry of Agriculture and Rural Affairs, indicating that the product meets relevant regulatory standards [2]. - The development of this product was a collaborative effort among Haizheng Animal Health and six other companies [2]. Group 2 - The new veterinary drug registration certificate signifies that the product is ready for production and market launch [2]. - Despite the approval, it is noted that there will be no significant short-term impact on the company's financial performance [2]. - This development is expected to enhance the company's competitiveness in the veterinary medicine market [2].

人民财讯12月18日电，海正药业（600267）12月18日公告，公司控股子公司海正动保公司收到农业农村 部核准签发的甲泼尼龙片(犬用)《新兽药注册证书》，该产品正式获批五类新兽药。甲泼尼龙片(犬用) 是海正动保公司等7家公司共同研制获批的五类新兽药。甲泼尼龙片(犬用)用于治疗犬炎症和过敏性疾 病，或作为炎症和过敏性疾病治疗方案的一部分。 ...

对于海正药业而言，其出售浙江医工的目的在于优化公司业务结构、聚焦医药工业的核心优势领域以提 升整体利润率与资源配置效益。 而在白云山看来，浙江医工地处长三角地区，医药市场发达，且是浙江省排名前6的优质医药流通企 业。同时，浙江医工一直深耕浙江省医药市场，积累了丰富的客户资源，最近一年年销售收入规模40亿 元以上，拥有良好的前景。 长江商报奔腾新闻记者 徐佳 海正药业（600267.SH）出售子公司敲定新买家。 12月17日晚间，白云山（600332.SH）披露资产收购计划。公司下属控股子公司广州医药股份有限公司 （"广州医药"）拟通过公开摘牌方式受让海正药业所持浙江省医药工业有限公司（"浙江医工"）100% 股权，转让价款为5亿元。 资料显示，浙江医工成立于1999年，是浙江省医药流通企业，拥有浙江省麻黄素、咖啡因及二类麻醉药 品的经营及配送资质，其配送网络覆盖浙江全省，业务以医院纯销及药店批发为主。 截至2025年9月末，浙江医工资产总额17.12亿元，负债总额13.5亿元，净资产3.62亿元。资产负债率达 到78.84%。 本次交易中，浙江医工100%股权对应的评估价值为3.92亿元，海正药业以4.3亿元 ...

证券日报网讯 12月17日晚间，海正药业（600267）发布公告称，截至本公告披露日，公司对控股、参 股子公司提供的对外担保总额为人民币266，600万元，占公司最近一期经审计净资产的31.96%，无逾 期担保情况。 ...

证券日报网讯12月17日晚间，海正药业（600267）发布公告称，公司将于2026年1月5日14：00召开2026 年第一次临时股东会。 ...

Group 1 - The core viewpoint of the article is that Guangzhou Pharmaceutical is strategically enhancing its business operations in the East China region by acquiring 100% equity of Zhejiang Yigong from Haizheng Pharmaceutical for 505 million yuan [1] - The acquisition was approved by the company's Strategic Development and Investment Committee during its 10th meeting in 2025 [1] - The transaction does not constitute a related party transaction or a major asset restructuring as defined by the regulations for listed companies [1] Group 2 - Guangzhou Pharmaceutical successfully won the bid for the acquisition on December 10, 2025, paying a deposit of 86 million yuan to the Taizhou Property Rights Exchange [1] - The formal agreement for the equity transfer was signed on December 17, 2025, with the total transfer price set at 500.5 million yuan [1]

Group 1 - Zhejiang Lingyu Pharmaceutical Co., Ltd. was recently established with a registered capital of 100 million RMB, focusing on drug production, wholesale, and technology import/export [1][2] - The legal representative of the company is Zhang Hongyao, and it is co-owned by Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. (55% stake) and Hisun Pharmaceutical Co., Ltd. (45% stake) [1][2] - The company is registered in Taizhou, Zhejiang Province, and its business scope includes drug production and wholesale, subject to regulatory approvals [1][2]

Core Viewpoint - Zhejiang Lingyu Pharmaceutical Co., Ltd. has been established with a registered capital of 100 million RMB, primarily focusing on drug production and wholesale, with significant shareholding from Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. and Zhejiang Haizheng Pharmaceutical Co., Ltd. [1] Group 1: Company Overview - Company Name: Zhejiang Lingyu Pharmaceutical Co., Ltd. [1] - Legal Representative: Zhang Hongyao [1] - Registered Capital: 100 million RMB [1] - Company Type: Other limited liability company [1] - Business Duration: Until December 17, 2025, with no fixed term thereafter [1] - Registration Authority: Taizhou Jiaojiang District Market Supervision Administration [1] Group 2: Shareholding Structure - Shareholder 1: Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. holds 55% [1] - Shareholder 2: Zhejiang Haizheng Pharmaceutical Co., Ltd. holds 45% [1] Group 3: Business Scope - Main Activities: Drug production and wholesale, subject to necessary approvals [1] - Additional Activities: Technology import and export, goods import and export, engineering and technology research and development, technical services, development, consulting, exchange, transfer, and promotion [1] - Sales of chemical products (excluding licensed chemical products) [1]